Navigation Links
New approach to Alzheimer's therapy
Date:7/30/2010

The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.

DZNE and LMU researchers have succeeded in identifying an enzyme known as alpha secretase, which cleaves the amyloid precursor protein (APP) without forming beta-amyloid. Up to this point three different candidates for this function had been under consideration, but the research team has now been able to show that the enzyme ADAM10 alone is responsible for the specific cleavage. Dr. Stefan Lichtenthaler and his team developed highly specific antibodies that can identify the different cleavage products of the precursor protein in the brain cells of mice and in human cell cultures. Using a special technique called RNA interference, the researchers managed to block each of the three genes that code for the three ADAM enzymes under suspicion. An analysis of the cleavage products revealed that the ADAM10 gene was the only one able to prevent the formation of beta-amyloids. They confirmed their results using mass spectrometry.

"In ADAM10 we have identified a target molecule that plays a central role in the development of the molecular processes in Alzheimer's disease. We know that ADAM10 is less active in Alzheimer patients," says Dr. Lichtenthaler. When ADAM10 is less active, the precursor protein is more likely to be cleaved in a way that promotes the formation of beta-amyloids.

"It is possible that less ADAM10 activity could increase susceptibility to Alzheimer's disease. If that is the case, stimulating ADAM10 could be an important mechanism for therapy. But our antibodies also open up new possibilities for diagnosing and preventing the disease," says Lichtenthaler. The antibodies could be used to measure ADAM10 activity in spinal fluid and, by extension, identify persons who may have an increased risk of developing Alzheimer's disease. A series of experiments to examine this possibility is already underway.


'/>"/>

Contact: Sonja Juelich-Abbas
sonja.juelich-abbas@dzne.de
49-228-433-02260
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Discovery points to new approach for diabetes therapy
2. Personalized approach to smoking cessation may be reality in 3-5 years
3. Stem-cell therapy may provide new approach to fight infection
4. Insight into cells could lead to new approach to medicines
5. Entrust Credentialing Services - A New End-to-End, SAAS Approach for Identity-Based Smartcards
6. No more pills: Male contraceptive takes new approach
7. Epigenetic concepts offer new approach to degenerative disease
8. Dual approach gives a more accurate picture of the autistic brain
9. Development of new anti-cancer gene therapy approach using lentiviral vectors
10. Asexual plant reproduction may seed new approach for agriculture
11. Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... Surface Plasmon Resonance (SPR) is ... optical phenomenon that is sensitive to changes in the dielectric properties of the medium ... changes in refractive index occurring up to 300 nm above the metal surface (Au) ...
(Date:2/28/2017)... 2017  Phosphorus, a computational genomics and clinical ... the Phosphorus Scientific Advisory Board, an established group ... the company on the development of new products ... visit http://phosphorus.com/about-us/ to learn more about ... gathered some of the top leaders in the ...
(Date:2/28/2017)... 28, 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases ... fourth quarter and full year ended December 31, ... recent business and clinical highlights. "During ... development pipeline by starting five clinical trials across ...
(Date:2/28/2017)... MA (PRWEB) , ... February 28, 2017 , ... ... clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel ... celebrating 15 years of meeting this unique need within the biotechnology and pharmaceutical ...
Breaking Biology Technology: